KYIV. June 15 (Interfax-Ukraine) – Private joint-stock company Darnitsa Pharmaceutical Firm (Kyiv) saw a 47.8% rise in net profit in 2014, to UAH 295.955 million, the company said in an offering memorandum.
The company said that its net revenue grew by 2.5% in 2014, to UAH 1.2 billion, and gross profit rose by 15%, to UAH 813.953 million.
In Q1 2015, net profit more than doubled, to UAH 220.503 million.
As reported, shareholders in Darnitsa Pharmaceutical Firm at a general meeting on April 15 supported the decision of the supervisory board of December 19, 2014 to place name bonds worth UAH 1 billion.
A total of 100,000 bonds will be issued in a book-entry form with a face value of UAH 1,000. The securities will be placed on the PFTS stock exchange (Kyiv) with the participation of underwriter UkrSibbank (Kharkiv).
The company is among the top-ten largest pharmaceutical producers of Ukraine and is one of the top-ten largest suppliers to hospitals.
